Italy· 045494010
VOSEVI*28 cpr rivestite 400 mg + 100 mg + 100 mg flacone
A sofosbuvir, velpatasvir and voxilaprevir product containing sofosbuvir/velpatasvir/voxilaprevir, registered in Italy by GILEAD SCIENCES IRELAND UC, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Sofosbuvir, velpatasvir and voxilaprevir is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AP56 (sofosbuvir, velpatasvir and voxilaprevir), each read from that country’s own register.
- This record: Italy
- 10 of them publish a price we can compare per daily dose
Sofosbuvir, velpatasvir and voxilaprevir · ATC J05AP56
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of sofosbuvir, velpatasvir and voxilaprevir costs, country by country.
Normalised to the WHO defined daily dose (0.4 g), the median price runs from $447.39 in Switzerland to $1097.10 in Italy — a ×2.5 gap.
- Italy: $1097.10 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Sofosbuvir, velpatasvir and voxilaprevir · price per daily dose (0.4 g)
USD · FX 28 Sept 2026
- IT Italy$1097.10
- CH Switzerland$447.39
The record
At a glance
- Active substance
- Sofosbuvir/Velpatasvir/Voxilaprevir
- Manufacturer
- GILEAD SCIENCES IRELAND UC
- Country
- Italy (IT)
- ATC code
- J05AP56
- ATC class
- Sofosbuvir, velpatasvir and voxilaprevir
- Defined daily dose
- 0.4 g, O
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic045494010VOSEVI*28 cpr rivestite 400 mg + 100 mg + 100 mg flaconeEUR 26982.04
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J05AP56
Sofosbuvir, velpatasvir and voxilaprevir, as other registers publish it.
- IcelandVoseviGilead Sciences Ireland UC*
- PolandVoseviGilead Sciences Ireland UC
- United StatesVoseviGilead Sciences, Inc.
- IcelandVoseviGilead Sciences Ireland UC*
- FinlandVoseviGilead Sciences Ireland UC
- DenmarkVoseviGilead Sciences Ireland UC
- FinlandVoseviGilead Sciences Ireland UC
- DenmarkVoseviGilead Sciences Ireland UC
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3a3263c3-f87d-47ca-82ab-9f5f6dd426c1 GET /v1/drugs/3a3263c3-f87d-47ca-82ab-9f5f6dd426c1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 26982.04,
"source": "aifa",
"currency": "EUR",
"strength": "SOFOSBUVIR+VELPATASVIR+VOXILAPREVIR 400+100+100MG 28 UNITA' USO ORALE",
"substance": "Sofosbuvir/Velpatasvir/Voxilaprevir",
"equivalence_group": "KJE",
"transparency_flag": null
}See everything about sofosbuvir, velpatasvir and voxilaprevir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.